See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Alcon commercially launches Tryptyr (acoltremon ophthalmic solution) 0.003% for signs and symptoms of DED in the US

Summary by optometrytimes.com
The solution was approved by the US Food and Drug Administration in late May 2025.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

optometrytimes.comoptometrytimes.com

Alcon commercially launches Tryptyr (acoltremon ophthalmic solution) 0.003% for signs and symptoms of DED in the US

The solution was approved by the US Food and Drug Administration in late May 2025.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

optometrytimes.com broke the news in on Friday, August 1, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States icon

United States

News
For You
SearchBlindspotLocal